Five claims, checked against the record.

Kratom is a plant in the coffee family. While some of its compounds interact with opioid receptors, they do so differently from classical opioids — acting as partial agonists with limited recruitment of the signaling pathway associated with respiratory depression, the mechanism that makes opioid overdoses lethal. Controlled laboratory studies, including direct-observation human research at NIDA, found no respiratory depression at typical consumer servings, and animal studies could not produce opioid-like respiratory failure even at doses many times human intake. The 2024 Frontiers in Pharmacology review states plainly that kratom is more accurately characterized as a substance with diverse, complex pharmacology.

Kratom-associated deaths are rare and almost always involve other substances. In the CDC's analysis of over 27,000 overdose deaths across 27 states, kratom was detected in 91 — and all but seven of those had documented polysubstance exposure; comprehensive follow-up testing of the remaining cases with available samples revealed other potentially lethal substances. The FDA's own current language acknowledges that in the rare deaths associated with kratom, it was usually used in combination with other drugs and its contribution is unclear. For scale: federal poison-control data for 2021 recorded 4 deaths associated with single-substance kratom exposures, against more than 80,000 opioid-attributed overdose deaths nationally that year. Every death matters — which is exactly why the real killers in these tragedies, adulterated products and dangerous drug combinations, are what regulation should target.

The National Institute on Drug Abuse's assessment is that preliminary data suggest a minority of consumers report withdrawal symptoms and a smaller minority report substance-use-disorder symptoms — and when dependence does occur, research finds it is generally mild, most often resembling the tolerance and withdrawal profile of daily caffeine use rather than that of opioids. The World Health Organization's Expert Committee on Drug Dependence reviewed kratom in 2021 and declined to recommend international scheduling. Dependence risk is real and should be communicated honestly on product labels — a KCPA requirement — but it is not the profile of a high-risk controlled substance.

The most consequential distinction in today's marketplace is between natural-leaf kratom products and chemically manipulated 7-OH products — concentrated substances engineered to elevate 7-hydroxymitragynine far beyond anything found in the natural leaf, frequently sold under kratom's name. These products carry a fundamentally different risk profile, and their spread is the strongest argument for the product standards, labeling requirements, and age restrictions in the Kratom Consumer Protection Act. Judging the kratom leaf by these products is like judging coffee by grain alcohol.

The federal government examined this question directly. When the U.S. Department of Health and Human Services rescinded the proposal to schedule kratom in 2018, it warned that a ban carried foreseeable public-health consequences — including the risk of pushing people who rely on kratom back toward far deadlier opioids. That is why the policy trend is running the other way: states that initially banned kratom are now reconsidering, and a growing majority of states that have acted have chosen regulation through the KCPA over prohibition. Bans hand the market to unregulated sellers; regulation sets standards and holds sellers to them.